 |
市场调查报告书
商品编码
1477243
糖尿病肾病变市场，按药物类别、按给药途径、按配销通路、按地理位置Diabetic Kidney Disease Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
价格
简介目录
预计2024年全球糖尿病肾病变市场价值为30.3亿美元，预计到2031年将达42.1亿美元，2024年至2031年年复合成长率(CAGR)为4.8%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2023年 | 2024 年市场规模： | 30.3 亿美元 |
| 历史数据： | 2019年至2023年 | 预测期： | 2024年至2031年 |
| 预测 2024 年至 2031 年复合年增长率： | 4.80% | 2031 年价值预测： | 42.1 亿美元 |
图 1. 2024 年糖尿病肾病变市场占有率 (%)（按地区）
糖尿病肾病变（DKD）是一种因长期糖尿病而导致肾臟受损的疾病。随着时间的推移，糖尿病引起的高血糖会损害肾臟的小血管以及肾臟内的过滤单位（肾小球）。如果不能有效控制，肾小球损伤会降低肾功能，并可能导致肾衰竭。随着全球糖尿病盛行率的不断上升，糖尿病肾病变的治疗市场预计在不久的将来将稳定成长。
市场动态：
由于全球糖尿病和肥胖症盛行率不断上升，全球糖尿病肾病变市场正在显着成长。推动市场成长的一些关键驱动因素包括更容易患慢性肾病的老年人口的增加、对 DKD 早期诊断和治疗的认识不断提高，以及美国 FDA 越来越多地批准治疗 DKD 的新药。然而，肾衰竭治疗相关的高成本以及低收入地区缺乏疾病意识等因素可能会阻碍市场成长。持续不断的研发工作旨在开发更有效且安全性更高的药物，为市场参与者提供了利润丰厚的机会。预计世界各国政府在肾臟保健方面的医疗支出增加将在预测期内创造积极的商业环境。
研究的主要特点：
- 该报告对全球糖尿病肾病变市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
- 它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
- 这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
- 它根据以下参数描述了全球糖尿病肾病变市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
- 该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球糖尿病肾病变市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
- 利害关係人可以透过用于分析全球糖尿病肾病变市场的各种策略矩阵轻鬆做出决策。
目录
第一章：研究目标与假设
- 研究目标
- 假设
- 缩写
第 2 章：市场范围
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map (COM)
第 3 章：市场动态、法规与趋势分析
- 市场动态
- 司机
- 限制
- 市场机会
- 影响分析
- 市场走向
- 最近的发展
- 收购和合作场景
- 技术概览
- 监管场景
- 定价分析
- PEST分析
第 4 章：全球糖尿病肾病变市场 - 冠状病毒 (COVID-19) 大流行的影响
- 整体影响
- 政府倡议
- COVID-19 对市场的影响
第 5 章：2019 - 2031 年全球糖尿病肾病变市场（按药物类别）（十亿美元）
- 概述
- 血管张力素受体阻断剂 (ARB)
- 钙通道阻断剂
- 抗氧化发炎调节剂
- 血管紧张素转换酶 (ACE) 抑制剂
- 其他的
第 6 章：2019 - 2031 年全球糖尿病肾病变市场（按给药途径）（十亿美元）
- 概述
- 口服
- 注射用
第 7 章：全球糖尿病肾病变市场，依配销通路，2019 - 2031 年（十亿美元）
- 概述
- 医院药房
- 零售药局
- 网路药局
第 8 章：2019 - 2031 年全球糖尿病肾病变市场（按地区）（十亿美元）
- 介绍
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 欧洲其他地区
- 亚太地区
- 中国
- 印度
- 日本
- 东协
- 澳洲
- 韩国
- 亚太地区其他地区
- 中东
- 海湾合作委员会
- 以色列
- 中东其他地区
- 非洲
- 北非
- 中非
- 南非
第 9 章：竞争格局
- 公司简介
- AstraZeneca
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Bristol Myers Squibb
- GSK
- Novo Nordisk
- Eli Lilly and Company
- Merck & Co.
- Sanofi
- AbbVie
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Lupin
- Aurobindo Pharma
- Takeda Pharmaceutical Company Limited
- Biogen
- Vertex Pharmaceuticals Incorporated
第 10 章：分析师观点
- 命运之轮
- 分析师观点
- 连贯的机会图
第 11 章：参考文献与研究方法
- 参考
- 研究方法论
简介目录
Product Code: CMI6852
Global diabetic kidney disease market is estimated to be valued at USD 3.03 Bn in 2024 and is expected to reach USD 4.21 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 3.03 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.80% | 2031 Value Projection: | US$ 4.21 Bn |
Figure 1. Diabetic Kidney Disease Market Share (%), By Region, 2024
Diabetic kidney disease (DKD) is a condition in which the kidneys are damaged due to long-standing diabetes. Over time, high blood sugar from diabetes can damage both the small blood vessels in the kidneys as well as the filtering units (glomeruli) within the kidneys. Damage to the glomeruli can reduce kidney function and may lead to kidney failure, if not controlled effectively. With increasing prevalence of diabetes globally, the market for treatments of diabetic kidney disease is projected to grow steadily in the near future.
Market Dynamics:
Global diabetic kidney disease market is witnessing significant growth due to rising prevalence of diabetes and obesity worldwide. Some of the key drivers fueling the market growth include growing geriatric population who are more susceptible to chronic kidney diseases, rising awareness about early diagnosis and treatment of DKD, and increasing U.S. FDA approvals of novel drugs to treat DKD. However, factors such as high costs associated with kidney failure treatments and lack of diseases awareness in low-income regions can hamper the market growth. Ongoing R&D efforts to develop more efficacious drugs with improved safety profiles provide lucrative opportunities for market players. Increasing health expenditures of governments worldwide on kidney care is anticipated to create a positive business environment during the forecast period.
Key Features of the Study:
- This report provides in-depth analysis of the global diabetic kidney disease market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global diabetic kidney disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, and Vertex Pharmaceuticals Incorporated.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global diabetic kidney disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic kidney disease market.
Detailed Segmentation-
- Drug Class:
- Angiotensin Receptor Blockers (ARBs)
- Calcium Channel Blockers
- Antioxidant Inflammation Modulator
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Others
- Route of Administration:
- Oral
- Parenteral
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- AstraZeneca
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Bristol Myers Squibb
- GSK
- Novo Nordisk
- Eli Lilly and Company
- Merck & Co.
- Sanofi
- AbbVie
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Lupin
- Aurobindo Pharma
- Takeda Pharmaceutical Company Limited
- Biogen
- Vertex Pharmaceuticals Incorporated
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Diabetic Kidney Disease Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Diabetic Kidney Disease Market, By Drug Class, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Angiotensin Receptor Blockers (ARBs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Calcium Channel Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Antioxidant Inflammation Modulator
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
6. Global Diabetic Kidney Disease Market, By Route of Administration, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
7. Global Diabetic Kidney Disease Market, By Distribution Channel, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
8. Global Diabetic Kidney Disease Market, By Region, 2019 - 2031, (USD BN)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Bristol Myers Squibb
- GSK
- Novo Nordisk
- Eli Lilly and Company
- Merck & Co.
- Sanofi
- AbbVie
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Lupin
- Aurobindo Pharma
- Takeda Pharmaceutical Company Limited
- Biogen
- Vertex Pharmaceuticals Incorporated
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
